Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple tumoricidal effector mechanisms induced by adriamycin.

D Salazar, S A Cohen

    Cancer Research
    |June 1, 1984
    PubMed
    Summary

    Adriamycin treatment enhances antitumor cytotoxicity of mouse peritoneal cells, particularly neutrophils, against specific tumor cells. This effect involves drug presence and reactive oxygen species, with distinct mechanisms observed at different time points post-injection.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Development of an automated quality control and assay performance management system for biochemical genetics laboratory.

    Molecular genetics and metabolism reports·2025
    Same author

    Clinical Comparison of Three Indirect Pulp Capping Restorative Protocols: A Randomized Controlled Prospective Study.

    Operative dentistry·2024
    Same author

    A diagnostic to measure neutral-atom density in fusion-research plasmas.

    The Review of scientific instruments·2022
    Same author

    Evaluation of a collisional radiative model for electron temperature determination in hydrogen plasma.

    The Review of scientific instruments·2022
    Same author

    Use of a Mylar filter to eliminate vacuum ultraviolet pulse pileup in low-energy x-ray measurements.

    The Review of scientific instruments·2022
    Same author

    Simulating single-particle dynamics in magnetized plasmas: The RMF code.

    The Review of scientific instruments·2022

    Area of Science:

    • Immunology
    • Pharmacology
    • Cancer Research

    Background:

    • Adriamycin (doxorubicin) is a chemotherapy drug with known cytotoxic effects.
    • The role of immune cells in Adriamycin's antitumor activity requires further elucidation.
    • Peritoneal exudate cells (PECs) are a readily accessible source of immune cells for studying drug-induced immune responses.

    Purpose of the Study:

    • To investigate the antitumor cytotoxic mechanisms of Adriamycin-elicited peritoneal exudate cells.
    • To differentiate the roles of various immune cell types (neutrophils, macrophages, lymphocytes) in Adriamycin-mediated cytotoxicity.
    • To explore the involvement of reactive oxygen species (ROS) in the observed cytotoxic effects.

    Main Methods:

    • Mice were injected with Adriamycin (10 mg/kg) and PECs were collected at 1 day and 5-7 days post-injection.
    • Cytotoxicity assays (e.g., chromium release) were performed using P815 (macrophage-sensitive) and YAC-1 (natural killer-sensitive) tumor cell lines.
    • Freeze-thaw lysates of PECs were used to assess the nature of the effector moiety.
    • Production of superoxide anion and hydrogen peroxide (H2O2) was measured in response to phorbol myristate acetate (PMA).
    • Catalase inhibition assays were used to determine the role of ROS.

    Main Results:

    • PECs collected 1 day post-Adriamycin showed enhanced cytotoxicity against P815, correlating with intracellular drug concentration.
    • Lytic activity of these early PECs was associated with insoluble effector moieties and ROS production (superoxide, H2O2) upon PMA stimulation.
    • Neutrophils, not macrophages, were implicated in the PMA-augmented cytotoxicity.
    • Lymphocytes from mice treated 5-7 days prior were cytotoxic to YAC-1.
    • Macrophages from mice treated 5-7 days prior were cytotoxic to P815 independently of detectable Adriamycin, with PMA inhibiting this lysis.

    Conclusions:

    • Adriamycin elicits distinct cytotoxic immune cell responses at different time points.
    • Early responses (1 day) involve drug-dependent cytotoxicity by neutrophils, potentially mediated by ROS.
    • Later responses (5-7 days) involve drug-independent cytotoxicity by lymphocytes and macrophages, with differing sensitivities to stimuli.
    • These findings highlight the complex interplay between chemotherapy and the immune system in antitumor responses.

    Related Experiment Videos